Role of BCG in Treatment of Bladder Cancer

Abhishek Singhal

Abhishek Singhal Smt. Kashibai Navale College of Pharmacy

Keywords: Bacillus Calmette-Guérin, mmunotherapy, Cancer Treatment

Abstract

Aim: This review is written to describe the role of immunotherapy in cancer treatment.
Annually, 13,000 deaths result from bladder cancer. Since the first report of intravesical use of BCG in 1976, investigators try to understand the working mechanism of BCG as an antitumour modality. Arbitrarily, BCG therapy consists of a single course of six weekly intravesical instillations. Bacillus Calmette-Gue´rin, an attenuated strain of Mycobacterium bovis, was developed by Calmette and Gue´rin with the intention to generate a vaccine against tuberculosis. Extension of BCG treatment (maintenance immunotherapy) is used to increase efficacy.
Results of various experiments describe that after instillation in the bladder, BCG accumulates near the bladder wall and is internalised and processed by professional antigen-presenting cells (APCs) and (high-grade) tumour cells. Then BCG antigens are presented to CD4+ T cells. Then local synthesis of a particular set of cytokines or cell-mediated immune response. NK cells may be involve in tumour cell killing.

Author Biography

Abhishek Singhal, Smt. Kashibai Navale College of Pharmacy

Department of Pharmacology,
Smt. Kashibai Navale College of Pharmacy, Kondhwa (Bk.),
Pune, Maharastra, India

References

1. Bevers, R.F.M. et al., Role of urothelial cells in BCG immunotherapy for superficial bladder cancer. British Journal of Cancer, 2004, 91, 607–612.
2. Brandau, S. et al., NK cells are essential for effective bcg immunotherapy. Int J Cancer, 2001, 92, 697–702.
3. Ludwig, A. T. et al., Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand: A Novel Mechanism for Bacillus Calmette-Guérin-Induced Antitumor Activity. Cancer Res, 2004, 64, 29–35.
4. Suttmann, H. et al., Neutrophil granulocytes are required for effective bacillus calmette-guérin immunotherapy of bladder cancer and orchestrate local immune responses. Cancer Res, 2006, 66, 8250-8257.
5. Luo, Y. et al., Role of Th1-stimulating cytokines in bacillus Calmette–Guérin (BCG)-induced macrophage cytotoxicity against mouse bladder cancer MBT-2 cells. Clinical and Experimental Immunology, 2006, 146, 181–188.
6. Ikeda, N. et al., Surface antigen expression on bladder tumor cells induced by bacillus Calmette-Guérin (BCG): A role of BCG internalization into tumor cells. International Journal of Urology, 2002, 9, 29–35.
7. Jackson, A.M. et al., Changes in urinary cytokines and soluble intercellular adhesion molecule-1 (ICAM-l) in bladder cancer patients after Bacillus Calmette-Guerin (BCG) immunotherapy. Clin Exp Immunol, 1995, 99, 369-375.